This is a phase II precision medicine cancer trial with nearly 40 treatment arms. See study details. Patients with advanced solid tumors, lymphomas, or myeloma may be eligible, once they have progressed on standard treatment for their cancer or if they have a rare cancer for which there is no standard treatment. Some arms have exceptions. Each arm targets a unique gene abnormality known to drive cancer growth. Many of these driver mutations occur only rarely in patients, as shown by the posted frequency rates. These are the rates found in the first 6,000 patients tested in this trial. See the table below for the open treatment arms.
Total accrual: 995 as of 07/08/2019
http://ecog-acrin.org/trials/nci-match-eay131
For more information: Cincinnati Children’s Division of Hematology / Oncology | Phone: 513-636-2799 | Email: cancer@cchmc.org
|
TARGET
|
STUDY / ID
|
ACCRUAL
|
AGENT
|
DISEASE EXCEPTIONS
|
DATE ACTIVATED
|
STATUS
|
|
EGFR Activating Mutations
(0.05% frequency)
|
A
|
35 (9)
|
Gilotrif® (afatinib)
|
Small cell cancer, non-small cell lung cancer (NSCLC)
|
8/12/2015
|
OPEN
|
|
MET Exon 14 Deletion
(0.61% frequency)
|
C2
|
35 (18)
|
Xalkori® (crizotinib)
|
None
|
5/31/2016
|
OPEN
|
|
EGFR T790M (with/without an activating mutation) or Rare Activating Mutations of EGFR
(0.11% frequency)
|
E
|
35 (9)
|
AZD9291
|
NSCLC
|
8/12/2015
|
OPEN
|
FGFR Mutations or Fusions
(1.00% frequency) |
K2 |
35 (32) |
erdafitinib |
Transitional cell carcinoma of the bladder and/or urothelial tract |
6/20/2018 |
OPEN |
|
mTOR Mutations
(0.31% frequency)
|
L
|
35 (16)
|
TAK-228 (formerly MLN0128)
|
None
|
3/13/2017
|
OPEN
|
|
Smoothened (SMO) or Patched 1 (PTCH1) Mutations
(0.42% frequency)
|
T
|
35 (28)
|
Erivedge® (vismodegib)
|
Basal cell skin cancer
|
2/23/2016
|
OPEN
|
|
cKIT Mutations
(0.11% frequency)
|
V
|
35 (9)
|
Sutent® (sunitinib malate)
|
Gastrointestinal stromal tumors (GIST), renal cell carcinoma, or pancreatic neuroendocrine tumors
|
8/12/2015
|
OPEN
|
|
NTRK Fusions
(0.10% frequency)
|
Z1E
|
35 (7)
|
larotrectinib
|
None
|
3/13/2017
|
OPEN
|
PTEN Loss by Immunohistochemistry without PIK3CA Mutations
(1.93% frequency) |
Z1G |
35 (6) |
copanlisib |
Indolent non-Hodgkin’s lymphoma, diffuse large B cell lymphoma, or HER2-positive breast cancer |
6/20/2018 |
OPEN |
PTEN (deleterious) Seq Result and PTEN Expression by Immunochemistry
(1.75% frequency) |
Z1H |
35 (16) |
copanlisib |
Indolent non-Hodgkin’s lymphoma, diffuse large B cell lymphoma, or HER2-positive breast cancer |
6/20/2018 |
OPEN |
AKT mutations
(0.77% frequency)
|
Z1K |
35 (0) |
ipatasertib |
None |
7/25/2019 |
OPEN |
Non-V600 BRAF mutations
(0.80% frequency)
|
Z1K |
35 (0) |
ulixertinib (BVD-523) |
None |
7/25/2019 |
OPEN |